Vascular Graft Solutions

Executive Summary

Vascular Graft Solutions (VGS) is an Israeli medtech company dedicated to improving outcomes in coronary artery bypass grafting (CABG). Its lead product, VEST, is an external stent designed to reduce saphenous vein graft failure, which is a major cause of repeat revascularization. The company also offers VIOLA, a clampless proximal anastomosis device that aims to lower stroke and neurocognitive complications during CABG. By addressing these critical complications, VGS targets a large and growing market: over 400,000 CABG procedures are performed annually in the U.S. alone, with vein graft failure rates exceeding 10-15% at one year. VGS's technologies have the potential to significantly improve patient quality of life and reduce healthcare costs by avoiding repeat procedures and managing complications. The company is in the commercial stage, with VEST and VIOLA both CE-marked and available in select markets. However, adoption in the U.S. is pending FDA 510(k) clearances and additional clinical data.

Upcoming Catalysts (preview)

• Q2 2027FDA 510(k) clearance for VEST external stent65% success
• Q4 2026One-year outcomes from VEST pivotal trial75% success
• Q3 2026Expansion into European markets via new distribution agreements80% success